This might include one or more of the following medications: dulaglutide (Trulicity) exenatide (Bydureon) liraglutide (Victoza, Saxenda) lixisenatide (Adlyxine) semaglutide (Ozempic, Rybelsus, Wegovy) These are GLP-1 receptor agonists that the FDA has approved for conditions such as: managing type 2 diabetes obesity fatty liver disease improving cardiovascular health However, more research is needed to determine whether they may be effective in treating OSA
HS-20094 15 mg showed statistically greater reduction than semaglutide 1.0 mg
Analysts estimate a potential FDA submission in the 20262027 window , pending clean Phase 3 data
00:15:54 Craig Williams Yeah, and I was going to add briefly that when patients do lose a lot of weight, they feel so much better that we have had a couple patients who are the motivation kind of changes to keep the weight off when they get it off, maybe as opposed to trying to lose it kind of in the 1st place
With Votiva, results are noticeable and meaningful without the risks of invasive surgery
What Makes It Different
